Skip to results

Area of interest

Area of interest

Type (1 selected)


Guidance programme (1 selected)

Guidance programme

Showing 11 to 20 of 302

Guidance and quality standards awaiting development
Adalimumab for treating early Dupuytren's contracture TS ID 11870Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830Technology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Amivantamab with lazertinib for previously untreated locally advanced or metastatic non-small-cell lung cancer TS ID 11842Technology appraisal guidance
Amyotrophic lateral sclerosis - SAR443820 TS ID 11938Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All